Tomonori Yaguchi

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 8

Top Topics

Combination Therapy

Basal Cell Carcinoma

Top Venues

Experimental dermatology

The Journal of experimental medicine

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Yixin Zou, Tomonori Yaguchi
Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies. Experimental dermatology 32 (3) (2023)
Yixin Zou, Tomonori Yaguchi
PD-1 blockade therapy in melanoma: resistance mechanisms and combination strategies. Experimental dermatology (2023)
Yixin Zou, Tomonori Yaguchi
Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies. Experimental dermatology 32 (3) (2023)
Yixin Zou, Tomonori Yaguchi
Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies. Experimental dermatology 32 (3) (2023)
Yixin Zou, Tomonori Yaguchi
Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies. Experimental dermatology (2023)
Yuki Katoh, Tomonori Yaguchi, Akiko Kubo, Takashi Iwata, Kenji Morii, Daiki Kato, Shigeki Ohta, Ryosuke Satomi, Yasuhiro Yamamoto, Yoshitaka Oyamada, Kota Ouchi, Shin Takahashi, Chikashi Ishioka, Ryo Matoba, Makoto Suematsu, Yutaka Kawakami
Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody. Journal for immunotherapy of cancer 10 (7) (2022)
Keitaro Fukuda, Ken Okamura, Rebecca L Riding, Xueli Fan, Khashayar Afshari, Nazgol-Sadat Haddadi, Sean Matthew McCauley, Mehmet Hakan Guney, Jeremy Luban, Takeru Funakoshi, Tomonori Yaguchi, Yutaka Kawakami, Anastasia Khvorova, Katherine A Fitzgerald, John E Harris
AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma. The Journal of experimental medicine 218 (9) (2021)
Daiki Kato, Tomonori Yaguchi, Takashi Iwata, Yuki Katoh, Kenji Morii, Kinya Tsubota, Yoshiaki Takise, Masaki Tamiya, Haruhiko Kamada, Hiroki Akiba, Kouhei Tsumoto, Satoshi Serada, Tetsuji Naka, Ryohei Nishimura, Takayuki Nakagawa, Yutaka Kawakami
GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab. eLife 9 (2020)